| abstract |
The present invention relates to the field of improved anti-IgE antibodies and antigen-binding agents and combinations thereof that target IgE, for example, for treating conditions caused by IgE (such as allergic reactions, or certain autoimmune reactions); And especially disorders caused by the interaction of IgE with the FcyRI receptor. Specifically, the present invention relates to improved anti-IgE antibodies and antigen-binding agents related to novel mutants of omazumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the present invention have improved affinity for IgE and / or have improved interactions with the Cɛ2 domain of IgE and / or have modified epitopes on IgE (Eg, further involving the C 涉及 2 domain of IgE) and / or have the ability to dissociate IgE from the FcɛRI receptor at, for example, a pharmacologically relevant concentration. In one aspect, an improved or novel treatment for an IgE-mediated disorder is disclosed, wherein IgE is a target (eg, a complex of free IgE and / or IgE and the FcɛRI receptor). |